Literature DB >> 31131953

First estimate of the scale of canonical 5' splice site GT>GC variants capable of generating wild-type transcripts.

Jin-Huan Lin1,2,3, Xin-Ying Tang2,3, Arnaud Boulling1, Wen-Bin Zou2,3, Emmanuelle Masson1,4, Yann Fichou1,5, Loann Raud1, Marlène Le Tertre1, Shun-Jiang Deng2,3, Isabelle Berlivet1, Chandran Ka1,4,5, Matthew Mort6, Matthew Hayden6, Raphaël Leman7,8, Claude Houdayer8, Gerald Le Gac1,4,5, David N Cooper6, Zhao-Shen Li2,3, Claude Férec1, Zhuan Liao2,3, Jian-Min Chen1.   

Abstract

It has long been known that canonical 5' splice site (5'SS) GT>GC variants may be compatible with normal splicing. However, to date, the actual scale of canonical 5'SSs capable of generating wild-type transcripts in the case of GT>GC substitutions remains unknown. Herein, combining data derived from a meta-analysis of 45 human disease-causing 5'SS GT>GC variants and a cell culture-based full-length gene splicing assay of 103 5'SS GT>GC substitutions, we estimate that ~15-18% of canonical GT 5'SSs retain their capacity to generate between 1% and 84% normal transcripts when GT is substituted by GC. We further demonstrate that the canonical 5'SSs in which substitution of GT by GC-generated normal transcripts exhibit stronger complementarity to the 5' end of U1 snRNA than those sites whose substitutions of GT by GC did not lead to the generation of normal transcripts. We also observed a correlation between the generation of wild-type transcripts and a milder than expected clinical phenotype but found that none of the available splicing prediction tools were capable of reliably distinguishing 5'SS GT>GC variants that generated wild-type transcripts from those that did not. Our findings imply that 5'SS GT>GC variants in human disease genes may not invariably be pathogenic.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  canonical 5′ splice site; full-length gene splicing assay; genotype and phenotype relationship; human gene mutation database; human inherited disease; noncanonical splice donor site

Mesh:

Substances:

Year:  2019        PMID: 31131953     DOI: 10.1002/humu.23821

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Profiling of cis- and trans-acting factors supporting noncanonical splice site activation.

Authors:  Steffen Erkelenz; Gereon Poschmann; Johannes Ptok; Lisa Müller; Heiner Schaal
Journal:  RNA Biol       Date:  2020-08-05       Impact factor: 4.652

2.  Minigene Splicing Assays Identify 20 Spliceogenic Variants of the Breast/Ovarian Cancer Susceptibility Gene RAD51C.

Authors:  Lara Sanoguera-Miralles; Elena Bueno-Martínez; Alberto Valenzuela-Palomo; Ada Esteban-Sánchez; Inés Llinares-Burguet; Pedro Pérez-Segura; Alicia García-Álvarez; Miguel de la Hoya; Eladio A Velasco-Sampedro
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

3.  The Experimentally Obtained Functional Impact Assessments of 5' Splice Site GT'GC Variants Differ Markedly from Those Predicted.

Authors:  Jian-Min Chen; Jin-Huan Lin; Emmanuelle Masson; Zhuan Liao; Claude Férec; David N Cooper; Matthew Hayden
Journal:  Curr Genomics       Date:  2020-01       Impact factor: 2.236

Review 4.  Sequence and Evolutionary Features for the Alternatively Spliced Exons of Eukaryotic Genes.

Authors:  Shi-Yi Chen; Cao Li; Xianbo Jia; Song-Jia Lai
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

5.  Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia.

Authors:  Barbara Schmaltz-Panneau; Anne Pagnier; Séverine Clauin; Julien Buratti; Caroline Marty; Odile Fenneteau; Klaus Dieterich; Blandine Beaupain; Jean Donadieu; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

6.  EXT1 and EXT2 Variants in 22 Chinese Families With Multiple Osteochondromas: Seven New Variants and Potentiation of Preimplantation Genetic Testing and Prenatal Diagnosis.

Authors:  Ye Wang; Liangying Zhong; Yan Xu; Lei Ding; Yuanjun Ji; Sacha Schutz; Claude Férec; David N Cooper; Caixia Xu; Jian-Min Chen; Yanmin Luo
Journal:  Front Genet       Date:  2020-12-22       Impact factor: 4.599

7.  Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.

Authors:  Alberto Valenzuela-Palomo; Elena Bueno-Martínez; Lara Sanoguera-Miralles; Víctor Lorca; Eugenia Fraile-Bethencourt; Ada Esteban-Sánchez; Susana Gómez-Barrero; Sara Carvalho; Jamie Allen; Alicia García-Álvarez; Pedro Pérez-Segura; Leila Dorling; Douglas F Easton; Peter Devilee; Maaike Pg Vreeswijk; Miguel de la Hoya; Eladio A Velasco
Journal:  J Pathol       Date:  2021-12-28       Impact factor: 9.883

8.  Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies.

Authors:  Anya T Joynt; Taylor A Evans; Matthew J Pellicore; Emily F Davis-Marcisak; Melis A Aksit; Alice C Eastman; Shivani U Patel; Kathleen C Paul; Derek L Osorio; Alyssa D Bowling; Calvin U Cotton; Karen S Raraigh; Natalie E West; Christian A Merlo; Garry R Cutting; Neeraj Sharma
Journal:  PLoS Genet       Date:  2020-10-21       Impact factor: 5.917

Review 9.  Splicing in the Diagnosis of Rare Disease: Advances and Challenges.

Authors:  Jenny Lord; Diana Baralle
Journal:  Front Genet       Date:  2021-07-01       Impact factor: 4.599

10.  Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.

Authors:  Paola Nix; Erin Mundt; Bradford Coffee; Elizabeth Goossen; Bryan M Warf; Krystal Brown; Karla Bowles; Benjamin Roa
Journal:  Fam Cancer       Date:  2021-01-20       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.